SIOX — Sio Gene Therapies Income Statement
0.000.00%
Last trade - 00:00- $33.95m
- -$12.17m
- 22
- 39
- 77
- 43
Annual income statement for Sio Gene Therapies, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2018 March 31st | 2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 213 | 127 | 69.2 | 42.2 | 71.6 |
| Operating Profit | -213 | -127 | -69.2 | -42.2 | -71.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -221 | -129 | -72.2 | -32.6 | -71.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -222 | -129 | -72.6 | -32.4 | -71.9 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -222 | -129 | -72.6 | -32.4 | -71.9 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -222 | -129 | -72.6 | -32.4 | -71.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -16.5 | -8.02 | -2.93 | -0.621 | -0.982 |